Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis

Thisi is a multi-center, double-blind, active-controlled, randomized, parallel-group clinical trial to compare the efficacy and safety of CELBESTA® and CELEBREX® in patients with rheumatoid arthritis. The subject will receive two tablets twice daily for 6 weeks.

Inclusion criteria

• Anyone over the age of 19
• Subjects who are diagnosed as established rheumatoid arthritis at screening visit and before
• Pain greater than 40/100mm-VAS(Visual Analgue Scale) after wash-out period
• Patients who are taking oral corticosteroids without dosage change (within a range of prednisolone 10mg a day) at least 4weeks and more than 1 DMARDs at least 3 months from screening test
• Patients willing and able to provide signed informed consent after the nature of the study has been explained

Exclusion criteria

• History of angina pectoris or congestive heart failure at rest or minimum activity
• History of myocardial infarction or artherosclerosis
• Patients who had a coronary angioplaty or coronary artery bypass graft within 1 year
• History of stroke, transient ischemic attack or hepatitis within 2 years
• Patients who have uncontrolled hypertension at screening
• Patients who take the medicines that might effect the test results by study investigators or might cause a excessive risk to the patients

• Intra-articular corticosteroid injection within 4 weeks from screening
• biological DMARDs such as infliximab, adlimumab, entanercept, anakinara or abatacept wihin 6 months from randomization
• biological DMARDs such as rituximab within 1 year from randomization
• History of a malignant tumor (except for the patients whose tumor was removed and there's no recurrence within 5 years)
• Patients who have gastrointestinal bleeding or peptic ulcer (except scar) within 30 days
• History of a gastroesophageal surgery such as antigastric-secretion surgery or esophagogastrectomy (except a simple perforator surgery)
• Patients who have severe disability in GI, Kidney, Liver and Blood
• Pregnant women, Lactating women and Women of child-bering potential who are not using adequate means of contraception
• History of allergy to COX-2 inhibitors or sulphonamides or other NSAIDs
• Any condition that, in the view of the investigator, would interfere with study participation